Xu Y - Search Results

1

Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.

Zhou Y, Wang C, Zhu H, Lin Y, Pan B, Zhang X, Huang X, Xu Q, Xu Y, Sun Q. Zhou Y, et al. Among authors: xu q, xu y. PLoS One. 2016 Jun 23;11(6):e0158143. doi: 10.1371/journal.pone.0158143. eCollection 2016. PLoS One. 2016. PMID: 27336598 Free PMC article.

2

[Diagnosis and treatment of occult breast cancer: report of 23 cases].

Zhong Y, Sun Q, Huang HY, Zhou YD, Guan JH, Mao F, Lin Y, Xu YL. Zhong Y, et al. Among authors: xu yl. Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):716-8. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21122392 Chinese.

3

Headway in resistance to endocrine therapy in breast cancer.

Xu Y, Sun Q. Xu Y, et al. J Thorac Dis. 2010 Sep;2(3):171-7. doi: 10.3978/j.issn.2072-1439.2010.02.03.9. J Thorac Dis. 2010. PMID: 22263039 Free PMC article.

4

A case-control study on risk factors of breast cancer in China.

Xu YL, Sun Q, Shan GL, Zhang J, Liao HB, Li SY, Jiang J, Shao ZM, Jiang HC, Shen NC, Shi Y, Yu CZ, Zhang BN, Chen YH, Duan XN, Li B. Xu YL, et al. Arch Med Sci. 2012 May 9;8(2):303-9. doi: 10.5114/aoms.2012.28558. Arch Med Sci. 2012. PMID: 22662004 Free PMC article.

5

[Comparative analysis of early diagnostic tools for breast cancer].

Shen SJ, Sun Q, Xu YL, Zhou YD, Guan JH, Mao F, Lin Y, Wang XJ, Han SM. Shen SJ, et al. Among authors: xu yl. Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):877-80. doi: 10.3760/cma.j.issn.0253-3766.2012.11.018. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23291142 Chinese.

6

ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.

Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y, Sun Q. Zhong Y, et al. Among authors: xu y. Med Oncol. 2014 Mar;31(3):864. doi: 10.1007/s12032-014-0864-0. Epub 2014 Feb 12. Med Oncol. 2014. PMID: 24519209

7

Nanotrastuzumab in combination with radioimmunotherapy: Can it be a viable treatment option for patients with HER2-positive breast cancer with brain metastasis?

Wang X, Sun Q, Shen S, Xu Y, Huang L. Wang X, et al. Among authors: xu y. Med Hypotheses. 2016 Mar;88:79-81. doi: 10.1016/j.mehy.2015.12.014. Epub 2015 Dec 17. Med Hypotheses. 2016. PMID: 26880645

8

Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014).

Pan B, Yao R, Shi J, Xu QQ, Zhou YD, Mao F, Lin Y, Guan JH, Wang XJ, Zhang YN, Zhang XH, Shen SJ, Zhong Y, Xu YL, Zhu QL, Liang ZY, Sun Q. Pan B, et al. Among authors: xu qq, xu yl. Oncotarget. 2016 Jun 21;7(25):38864-38875. doi: 10.18632/oncotarget.8778. Oncotarget. 2016. PMID: 27102151 Free PMC article.

9

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.

Xu QQ, Pan B, Wang CJ, Zhou YD, Mao F, Lin Y, Guan JH, Shen SJ, Zhang XH, Xu YL, Zhong Y, Wang XJ, Zhang YN, Sun Q. Xu QQ, et al. Among authors: xu yl. Oncotarget. 2016 Sep 27;7(39):63571-63582. doi: 10.18632/oncotarget.11541. Oncotarget. 2016. PMID: 27566580 Free PMC article. Review.

10

TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.

Xu Q, Xu Y, Pan B, Wu L, Ren X, Zhou Y, Mao F, Lin Y, Guan J, Shen S, Zhang X, Wang C, Zhong Y, Zhou L, Liang Z, Zhao H, Sun Q. Xu Q, et al. Among authors: xu y. Oncotarget. 2016 Dec 6;7(49):81815-81829. doi: 10.18632/oncotarget.13245. Oncotarget. 2016. PMID: 27833085 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,307 results

Search Page

Filters